Andrew Mosholder, MD, MPH

Andrew Mosholder, MD, MPH, is a psychiatrist, pharmacoepidemiologist, and former FDA senior medical officer with 32 years of experience at FDA in clinical development and post-market drug safety. As a Kinexum consultant, he advises pharmaceutical and biotechnology companies on regulatory and clinical strategy, pharmacovigilance, pharmacoepidemiology, regulatory submissions, psychiatric drug development, real-world evidence, and post-market safety assessment.
Andrew has extensive experience in evaluating INDs, NDAs, clinical trial data, and post-marketing safety information and can advise clients on clinical development plans, protocol design, efficacy endpoints, psychiatric safety, and benefit-risk assessment for psychiatric drugs.
Andrew began his FDA career in the Division of Neuropharmacological Drug Products, where he spent his first decade evaluating the efficacy and safety of psychiatric drugs through review of INDs, NDAs, clinical trial data, and post-marketing safety information. He subsequently transitioned to FDA’s Office of Surveillance and Epidemiology, where his work focused on pharmacovigilance, observational safety studies, real-world evidence, and pharmacoepidemiology. He later served as a senior medical officer in FDA’s Division of Epidemiology I, conducting and overseeing studies on drugs in a variety of classes, using administrative claims and real-world data and serving as a principal or senior investigator on studies using FDA resources, including the Sentinel System and U.S. Medicare data.
While at the FDA, Andrew reviewed sponsor-proposed post-marketing studies, led and contributed to FDA-sponsored pharmacoepidemiology studies, and assessed whether emerging drug safety findings warranted additional study, labeling changes, risk mitigation, or other regulatory action.
Andrew earned his MD from the University of Virginia School of Medicine and his MPH from the Johns Hopkins Bloomberg School of Public Health. He completed psychiatry residency training at Virginia Commonwealth University and fellowship training in child and adolescent psychiatry at the University of Virginia. He is board-certified in psychiatry and child and adolescent psychiatry and is a Distinguished Life General Member of the American Academy of Child and Adolescent Psychiatry.